Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model

Journal of Urology

Volumn 188, Issue 2, 2012, Pages 607-614

  Kroeze, Stephanie G C ^a   Daenen, Laura G M ^a   Nijkamp, Maarten W ^a   Roodhart, Jeanine M L ^a   De Gast, Gijsbert C ^b   Bosch, J L H Ruud ^a   Jans, Judith J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

carcinoma; catheter ablation; immunotherapy; interleukin 2; kidney; renal cell

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SPLEEN; TUMOR IMMUNITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CATHETER ABLATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY TESTS, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SPLEEN;

EID: 84863721426     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.03.116     Document Type: Article

References (30)

1. D.M. Parkin, F. Bray, J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74
2. M. Sun, R. Thuret, F. Abdollah Age-adjusted incidence, mortality and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis Eur Urol 59 2011 135
3. A. Bex, E. Jonasch, Z. Kirkali Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials Eur Urol 58 2010 819
4. B.I. Rini, M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992
5. H. Van Poppel, S. Joniau, S.W. Van Gool Vaccine therapy in patients with renal cell carcinoma Eur Urol 55 2009 1333
6. A.Z. Dudek, M.F. Mescher, I. Okazaki Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma Am J Clin Oncol 31 2008 173
7. D. Jocham, A. Richter, L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 2004 594
8. J. Zhou, D. Weng, F. Zhou Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses Cancer Immunol Immunother 58 2009 1587
9. M.H. den Brok, R.P. Sutmuller, S. Nierkens Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity Br J Cancer 95 2006 896
10. G. Gravante, G. Sconocchia, S.L. Ong Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies Liver Int 29 2009 18
11. H. Kim, B.K. Park, C.K. Kim Spontaneous regression of pulmonary and adrenal metastases following percutaneous radiofrequency ablation of a recurrent renal cell carcinoma Korean J Radiol 9 2008 470
12. R.F. Sanchez-Ortiz, N. Tannir, K. Ahrar Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170 2003 178
13. M.H. den Brok, R.P. Sutmuller, R. van der Voort In situ tumor ablation creates an antigen source for the generation of antitumor immunity Cancer Res 64 2004 4024
14. M.T. Lotze, E.A. Grimm, A. Mazumder Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor Cancer Res 41 1981 4420
15. S.A. Rosenberg, J.C. Yang, D.E. White Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Ann Surg 228 1998 307
16. K.A. Smith Interleukin-2: inception, impact and implications Science 240 1988 1169
17. W.M. Kuhtreiber, S. Kodama, D.E. Burger Methods to characterize lymphoid apoptosis in a murine model of autoreactivity J Immunol Methods 306 2005 137
18. K. Fischer, A. Mackensen The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity Methods 31 2003 135
19. M.J. Schwartz, H. Liu, D.H. Hwang Antitumor effects of an imidazoquinoline in renal cell carcinoma Urology 73 2009 1156
20. T.T. Wissniowski, J. Hansler, D. Neureiter Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits Cancer Res 63 2003 6496
21. D.A. Kunkle, B.L. Egleston, R.G. Uzzo Excise, ablate or observe: the small renal mass dilemma - a meta-analysis and review J Urol 179 2008 1227
22. A. Zerbini, M. Pilli, A. Penna Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses Cancer Res 66 2006 1139
23. J. Banchereau, R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245
24. I.M. Desar, J.H. Jacobs, C.A. Hulsbergen-vandeKaa Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients Int J Cancer 129 2011 507
25. N. Kobayashi, N. Hiraoka, W. Yamagami FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis Clin Cancer Res 13 2007 902
26. F.F. Fagnoni, A. Zerbini, G. Pelosi Combination of radiofrequency ablation and immunotherapy Front Biosci 13 2008 369
27. V.K. Todorova, V.S. Klimberg, L. Hennings Immunomodulatory effects of radiofrequency ablation in a breast cancer model Immunol Invest 39 2010 74
28. O.J. Finn Cancer vaccines: between the idea and the reality Nat Rev Immunol 3 2003 630
29. M. Fishman, J. Seigne Immunotherapy of metastatic renal cell cancer Cancer Control 9 2002 293
30. J. Ozao-Choy, G. Ma, J. Kao The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2009 2514